Related Experiment Videos
[Rapid decrease of serum endothelin-1 levels after treatment with ACE inhibitors in chronic cardiac failure]
Insights
Angiotensin converting enzyme (ACE) inhibitor therapy significantly reduced elevated plasma endothelin-1 levels in patients with severe cardiac failure within 72 hours. This finding may explain some beneficial effects of ACE inhibitors in heart failure patients.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Context:
- Circulating endothelin-1 is elevated in cardiac failure, contributing to adverse effects.
- The impact of common medications on endothelin-1 levels in heart failure is not well understood.
- Endothelin-1 is a potent vasoconstrictor peptide implicated in cardiovascular disease.
Purpose:
- To investigate the effect of angiotensin converting enzyme (ACE) inhibitor therapy on plasma endothelin-1 levels in patients with severe cardiac failure.
- To determine if ACE inhibitors can modulate endothelin-1, a key factor in cardiac dysfunction.
Summary:
- Plasma endothelin-1 levels were measured in 24 patients with NYHA class III-IV cardiac failure before and after treatment with Captopril (an ACE inhibitor).
- A control group of 10 patients was monitored to account for environmental factors.
- ACE inhibitor therapy led to a significant decrease in plasma endothelin-1 levels within 72 hours (p < 0.02), though levels remained elevated compared to normal.
Impact:
- ACE inhibitor therapy demonstrates a rapid reduction in plasma endothelin-1 levels in severe cardiac failure.
- This reduction may contribute to the known therapeutic benefits of ACE inhibitors in managing heart failure.
- The findings support experimental data and suggest a mechanism for ACE inhibitor efficacy in cardiovascular conditions.
Abstract:
Circulating endothelin-1, a very strong peptide vasoconstrictor first discovered in 1988, is raised in cardiac failure. This increase contributes to the deleterious effects of cardiac failure. Although specific anti-endothelin drugs are under development in this condition, the effects of more commonly used drugs on circulating endothelin-1 levels are not well known. The aim of this study was to evaluate the effects of ACE inhibitor therapy on plasma endothelin-1 levels in cardiac failure. The plasma endothelin-1 levels were measured in 24 patients (stages III and IV of the NYHA classification), before and after treatment with angiotensin converting enzyme inhibitor (Captopril: test doses, then 75 mg/day). A control group of 10 paired patients was used to shake off the effects of bed rest and hospital salt-free diet. The initial endothelin-1 levels were high but equivalent in the control and study groups: 9.13 +/- 1.87 fmol/mL vs 8.98 +/- 1.92 fmol/mL. Plasma endothelin-1 decreased significantly in the study group 72 hours after beginning ACE inhibitor therapy (7.44 +/- 1.95, p < 0.02) but remained higher than normal (p < 0.01), whereas the values in the control group remained the same. This study demonstrates a decreases in plasma endothelin-1 levels 72 hours after onset of ACE inhibitor therapy in patients with stable severe cardiac failure. This results, already suggested by many experimental studies and certain ancillary clinical trials, could explain some of the beneficial effects of ACE inhibitors in this condition.